Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week

About this update from Eupraxia Pharmaceuticals, Inc.

Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week EoEHSS (EoE Histology Scoring System) is a standardized method used to monitor esophageal tissue damage in EoE patients. Sub scores of EoEHSS are reported to specifically evaluate the tissue inflammation and tissue architecture (which is a measure of fibrosis)EoEHSS sub scores for inflammation demonstrated improvements in all reported cohorts at both 12 weeks (n=31) and 36 weeks (n=27)EoEHSS sub scores for tissue architecture (fibrosis) demonstrated improvements across most reported cohorts at 12 and 36 weeksThe largest response in both the inflammatory and the architectural (fibrosis) sub scores was seen at the highest dose tested VANCOUVER, British Columbia, May 06, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the first release of sub score data from the Eosinophilic Esophagitis Histologic Scoring System (“EoEHSS”) in its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis ("EoE"). These data were also presented this week at the Digestive Disease Week (“DDW”) conference in Chicago. "EoEHSS is a diagnostic tool used by physicians conducting clinical trials in EoE patients to measure tissue health,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “It is an important, validated measurement of the severity of EoE disease in the esophagus of patients. EoEHSS has sub scores that measure specific indicators of inflammation and fibrosis. The sub-score data from the highest dose cohorts in the RESOLVE study were reported for the first time at DDW and demonstrated improvement in both inflammation and fibrosis following treatment with EP-104GI. This is consistent with the improvements we have seen in EoE symptoms and with our recently reported endoscope scoring (EREFS) data and suggests treatment with EP-104GI may have an important benefit for EoE patients.” Key highlights from the DDW presentation: ...

View stock analysis, news, and events for Eupraxia Pharmaceuticals, Inc.